Furthermore, we provide strong evidence that targeting the CK2α-DUB3 axis could be effective in suppressing tumor progression in ovarian cancer and other cancers harboring aberrantly upregulated YAP1 (Fig. 7F). Here, USP17L2 is linked to ovarian cancer.